CY1107850T1 - Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους - Google Patents
Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγουςInfo
- Publication number
- CY1107850T1 CY1107850T1 CY20081100025T CY081100025T CY1107850T1 CY 1107850 T1 CY1107850 T1 CY 1107850T1 CY 20081100025 T CY20081100025 T CY 20081100025T CY 081100025 T CY081100025 T CY 081100025T CY 1107850 T1 CY1107850 T1 CY 1107850T1
- Authority
- CY
- Cyprus
- Prior art keywords
- sup
- thiadiazylopiperazine
- aptropic
- algues
- product
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Φέρεται στο προσκήνιο ένωση του τύπου (I) (όπου Χ είναι Ο ή S και R1, R3, R4, και R5 φέρονται στο προσκήνιο μέσω του παρόντος) ή φαρμακευτικά αποδεκτό άλας αυτής (μία "Θειαδιαζολυλοπιπεραζινική Ένωση"), φαρμακευτικές συνθέσεις με Θειαδιαζολυλοπιπεραζινική Ένωση και μέθοδοι αποτροπής ή αγωγής έναντι του άλγους ασθενούς που περιλαμβάνουν τη χορήγηση σε ασθενή με χρεία λήψης δραστικού ποσού Θειαδιαζολυλοπιπεραζινικής Ένωσης.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36017202P | 2002-03-01 | 2002-03-01 | |
US41108402P | 2002-09-17 | 2002-09-17 | |
EP03743718A EP1487829B1 (en) | 2002-03-01 | 2003-02-28 | Thiadiazolylpiperazine derivatives useful for treating or preventing pain |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107850T1 true CY1107850T1 (el) | 2013-06-19 |
Family
ID=27791632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081100025T CY1107850T1 (el) | 2002-03-01 | 2008-01-08 | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους |
Country Status (11)
Country | Link |
---|---|
US (2) | US6974818B2 (el) |
EP (1) | EP1487829B1 (el) |
JP (1) | JP4663984B2 (el) |
AT (1) | ATE375341T1 (el) |
AU (1) | AU2003225617A1 (el) |
CY (1) | CY1107850T1 (el) |
DE (1) | DE60316779T2 (el) |
DK (1) | DK1487829T3 (el) |
ES (1) | ES2295609T3 (el) |
PT (1) | PT1487829E (el) |
WO (1) | WO2003074520A1 (el) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60234812D1 (de) | 2001-01-29 | 2010-02-04 | Shionogi & Co | Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält |
US6974818B2 (en) * | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
JP4695395B2 (ja) * | 2002-12-13 | 2011-06-08 | ニューロジェン・コーポレーション | 疼痛治療用の併用療法 |
ES2288641T3 (es) * | 2002-12-20 | 2008-01-16 | Dynogen Pharmaceuticals Inc. | Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta. |
US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
US7524515B2 (en) * | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
PL1492519T3 (pl) * | 2003-03-21 | 2007-04-30 | Dynogen Pharmaceuticals Inc | Sposób leczenia chorób dolnych dróg moczowych przez zastosowanie modulatorów podjednostki α2δ kanału wapniowego z modulatorami mięśni gładkich |
US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
US20050009841A1 (en) * | 2003-07-11 | 2005-01-13 | Zheng Guo Zhu | Novel amides useful for treating pain |
US7129235B2 (en) | 2003-07-11 | 2006-10-31 | Abbott Laboratories | Amides useful for treating pain |
PL1867644T3 (pl) * | 2003-07-24 | 2009-10-30 | Euro Celtique Sa | Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu |
DK1867644T3 (da) | 2003-07-24 | 2009-09-21 | Euro Celtique Sa | Heteroaryl-tetrahydropyridyl-forbindelser, der er anvendelige til behandling eller forebyggelse af smerte |
DK1648880T3 (da) | 2003-08-01 | 2010-05-10 | Euro Celtique Sa | Terapeutiske midler, der kan anvendes til behandling af smerte |
EP1664041B1 (en) * | 2003-09-22 | 2008-07-02 | Euro-Celtique S.A. | Phenyl-carboxamide compounds useful for treating pain |
US20050288298A1 (en) * | 2004-03-18 | 2005-12-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
CA2559285A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
US7485646B2 (en) * | 2004-09-09 | 2009-02-03 | Research Foundation Itsuu Laboratory | Serotonin 5-HT3 receptor agonist |
TW200633990A (en) * | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
AU2013211455B2 (en) * | 2005-09-19 | 2017-12-07 | Neuronascent, Inc. | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration |
KR101132378B1 (ko) * | 2005-09-19 | 2012-04-03 | 뉴로내슨트, 아이엔씨. | 신경발생을 자극 및 신경 퇴화를 억제하는 방법 및 조성물 |
EP1957112A2 (en) * | 2005-11-21 | 2008-08-20 | Pietro Paolo Sanna | Role of proteoglycans in drug dependence |
DE102005062986A1 (de) | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
CA2685266C (en) * | 2007-04-27 | 2014-01-28 | Purdue Pharma L.P. | Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal |
JP2011503075A (ja) * | 2007-11-09 | 2011-01-27 | ノバルティス アーゲー | エポチロンまたはエポチロン誘導体誘発下痢を処置するためのコルチコステロイド |
US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
CA2743717A1 (en) * | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
JP5876423B2 (ja) | 2010-06-22 | 2016-03-02 | 塩野義製薬株式会社 | Trpv1阻害活性を有する化合物とその使用 |
US9156830B2 (en) | 2011-05-17 | 2015-10-13 | Shionogi & Co., Ltd. | Heterocyclic compounds |
US9273043B2 (en) | 2011-06-22 | 2016-03-01 | Purdue Pharma L.P. | TRPV1 antagonists including dihydroxy substituent and uses thereof |
ES2887104T3 (es) | 2011-09-19 | 2021-12-21 | Orexo Ab | Comprimidos sublinguales resistentes al abuso que comprenden buprenorfina y naloxona |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
KR20190033599A (ko) | 2016-07-29 | 2019-03-29 | 얀센 파마슈티카 엔.브이. | 전립선암의 치료 방법 |
DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5316759A (en) * | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
US5198459A (en) * | 1987-07-11 | 1993-03-30 | Sandoz Ltd. | Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents |
DE3822792C2 (de) * | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
US5075341A (en) * | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
IL96891A0 (en) * | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
US6204284B1 (en) * | 1991-12-20 | 2001-03-20 | American Cyanamid Company | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies |
US5232934A (en) * | 1992-07-17 | 1993-08-03 | Warner-Lambert Co. | Method for the treatment of psychomotor stimulant addiction |
US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US5556837A (en) * | 1994-08-01 | 1996-09-17 | Regeneron Pharmaceuticals Inc. | Methods for treating addictive disorders |
US5762925A (en) * | 1994-11-03 | 1998-06-09 | Sagen; Jacqueline | Preventing opiate tolerance by cellular implantation |
AU742391B2 (en) | 1997-08-20 | 2002-01-03 | Regents Of The University Of California, The | Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof |
EP0943683A1 (en) | 1998-03-10 | 1999-09-22 | Smithkline Beecham Plc | Human vanilloid receptor homologue Vanilrep1 |
PT1140924E (pt) * | 1998-12-14 | 2006-08-31 | Astellas Pharma Inc | Derivados de piperazina |
CN1164580C (zh) * | 1999-03-03 | 2004-09-01 | 惠氏公司 | 用作5-羟色胺激活剂的二唑衍生物 |
GB9907097D0 (en) | 1999-03-26 | 1999-05-19 | Novartis Ag | Organic compounds |
US6109269A (en) * | 1999-04-30 | 2000-08-29 | Medtronic, Inc. | Method of treating addiction by brain infusion |
AU8066701A (en) | 2000-07-20 | 2002-02-05 | Neurogen Corp | Capsaicin receptor ligands |
EP1303483B1 (en) | 2000-08-21 | 2008-04-23 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
JP2004506714A (ja) * | 2000-08-21 | 2004-03-04 | パシフィック コーポレーション | 新規チオ尿素化合物及びこれを含有する薬学的組成物 |
PE20030417A1 (es) | 2001-09-13 | 2003-08-06 | Smithkline Beecham Plc | Derivados de urea como antagonistas del receptor vainilloide |
HUP0500200A2 (hu) | 2002-01-17 | 2005-07-28 | Neurogen Corporation | Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények |
AU2003245773A1 (en) | 2002-02-15 | 2003-09-04 | Glaxo Group Limited | Vanilloid receptor modulators |
US7074805B2 (en) * | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
US20030158188A1 (en) * | 2002-02-20 | 2003-08-21 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
US6974818B2 (en) * | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
-
2003
- 2003-02-27 US US10/374,863 patent/US6974818B2/en not_active Expired - Lifetime
- 2003-02-28 DK DK03743718T patent/DK1487829T3/da active
- 2003-02-28 ES ES03743718T patent/ES2295609T3/es not_active Expired - Lifetime
- 2003-02-28 WO PCT/US2003/006107 patent/WO2003074520A1/en active IP Right Grant
- 2003-02-28 AU AU2003225617A patent/AU2003225617A1/en not_active Abandoned
- 2003-02-28 AT AT03743718T patent/ATE375341T1/de active
- 2003-02-28 PT PT03743718T patent/PT1487829E/pt unknown
- 2003-02-28 EP EP03743718A patent/EP1487829B1/en not_active Expired - Lifetime
- 2003-02-28 DE DE60316779T patent/DE60316779T2/de not_active Expired - Lifetime
- 2003-02-28 JP JP2003572988A patent/JP4663984B2/ja not_active Expired - Fee Related
-
2005
- 2005-10-07 US US11/246,498 patent/US7342017B2/en not_active Expired - Lifetime
-
2008
- 2008-01-08 CY CY20081100025T patent/CY1107850T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2295609T3 (es) | 2008-04-16 |
DK1487829T3 (da) | 2008-02-11 |
JP2005525365A (ja) | 2005-08-25 |
WO2003074520A1 (en) | 2003-09-12 |
PT1487829E (pt) | 2007-12-24 |
US20040006091A1 (en) | 2004-01-08 |
US20060074090A1 (en) | 2006-04-06 |
US6974818B2 (en) | 2005-12-13 |
EP1487829B1 (en) | 2007-10-10 |
US7342017B2 (en) | 2008-03-11 |
EP1487829A1 (en) | 2004-12-22 |
DE60316779T2 (de) | 2008-07-17 |
ATE375341T1 (de) | 2007-10-15 |
JP4663984B2 (ja) | 2011-04-06 |
AU2003225617A1 (en) | 2003-09-16 |
DE60316779D1 (de) | 2007-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
WO2005056524A3 (en) | Therapeutic agents useful for treating pain | |
SE0401345D0 (sv) | Therapeutic compounds: Pyridine as scaffold | |
IS8502A (is) | Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar | |
SE0300010D0 (sv) | Novel Compounds | |
CY1109242T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου | |
SE0101387D0 (sv) | Novel compounds | |
CY1109037T1 (el) | Πιπεραζινες χρησιμες για θεραπεια πονου | |
MXPA05007857A (es) | Moduladores derivados de indol de receptores nucleares de hormonas esteroideas. | |
SE9900961D0 (sv) | Novel compounds | |
SE0401342D0 (sv) | Therapeutic compounds | |
SE9901573D0 (sv) | New compounds | |
SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0300908D0 (sv) | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them | |
GB0130677D0 (en) | Medicaments and novel compounds | |
SE0102440D0 (sv) | New compound | |
ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
UA83832C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и их применение | |
SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
GB0310726D0 (en) | Therapeutic agents | |
GEP20043227B (en) | 5HT1 Antagonists for Antidepressant Therapy | |
SE0302572D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE9802209D0 (sv) | Novel compounds | |
ATE447953T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis |